Immune System News and Research

RSS

Freiburg scientist receives ERC Starting Grant for NutrImmune project

The microbiologist and immunologist Prof. Dr. Andreas Diefenbach, Institute of Medical Microbiology and Hygiene, University of Freiburg Medical Centre, has been awarded a European Research Council "Starting Grant" for his project "NutrImmune". The ERC Starting Grant is one of Europe's most prestigious grants for young investigators.

1 Aug 2012

Teplizumab type I diabetes prevention study now enrolls younger children

A type I diabetes prevention study that is part of the TrialNet program at Vanderbilt is now enrolling children as young as 8 years old, following an FDA decision allowing the drug Teplizumab (anti-CD3) to be used in younger children.

1 Aug 2012

IL-10 may improve success rates of skin autografts

Scientists have found that the anti-inflammatory molecule, IL-10, may improve success rates of skin autografts (skin moved from one site of the body to another). This information provides a valuable drug target that may benefit burn and accident victims.

1 Aug 2012

Specific autoantibodies associated with blood vessel damage in the brain

The presence of specific autoantibodies of the immune system is associated with blood vessel damage in the brain. These findings were made by Marion Bimmler, a graduate engineer of medical laboratory diagnostics at the Max Delbr-ck Center for Molecular Medicine Berlin-Buch and Dr. Peter Karczewski of the biotech company E.R.D.E.-AAK-Diagnostik GmbH in studies on a rat model.

31 Jul 2012

Australia's top medical researchers for 2012 announced

Finalists for one of Australia’s longest running and most prestigious awards for medical research were announced today. This year’s winner will join a list of alumni winners that includes many of the country’s most respected scientists.

31 Jul 2012

TAU researcher reveals link between plant and human biology

Increasingly, scientists are uncovering surprising biological connections between humans and other forms of life. Now a Tel Aviv University researcher has revealed that plant and human biology is much closer than has ever been understood - and the study of these similarities could uncover the biological basis of diseases like cancer as well as other "animal" behaviors.

31 Jul 2012

Two new targets could enhance the body's defenses against West Nile and hepatitis C

Two new targets have been discovered for antiviral therapies and vaccines strategies that could enhance the body's defenses against such infectious diseases as West Nile and hepatitis C. The targets are within the infection warning system inside living cells.

31 Jul 2012

Hydroxychloroquine fails to modify HIV in patients not taking ART

The use of hydroxychloroquine does not reduce CD8 cell activation in HIV-infected patients not taking antiretroviral therapy, research shows.

30 Jul 2012

Promising implications for improving cellular immunotherapy for treatment of cancer

New research from the Trudeau Institute laboratory of Dr. Edward L. Pearce (Washington University) has promising implications for improving a treatment for cancer known as cellular immunotherapy. The findings were just published in the The Journal of Immunology.

30 Jul 2012

UTMB researchers receives NIH grant to develop engineered lung tissue for biomedical studies

University of Texas Medical Branch at Galveston researchers have been awarded a two-year, $1.25 million National Institutes of Health grant to develop a method of custom-growing human lung tissue to make a three-dimensional model for biomedical studies.

30 Jul 2012

Researchers describe new human tissue dendritic cell with cross-presenting function

Researchers in Newcastle and Singapore have identified a new type of white blood cell which activates a killing immune response to an external source - providing a new potential target for vaccines for conditions such as cancer or Hepatitis B.

30 Jul 2012

Scientists decipher molecular causes of life-threatening candida fungal infections

With infectious diseases, it is often not the pathogen itself, but rather an excessive inflammatory immune responses death, for instance as a result of organ damage. On intensive care units, sepsis is the second-most common cause of death worldwide. In patients with a severely compromised immune system specially, life-threatening candida fungal infections represent a high risk of sepsis.

30 Jul 2012

Early ART treatment delays AIDS-related health events in HIV-infected individuals

Further analyses of the landmark NIH-funded treatment-as-prevention study (HPTN 052) have found that providing antiretroviral treatment to HIV-infected individuals earlier, when their immune systems are healthier, delays AIDS-related health events, such as chronic herpes simplex virus and tuberculosis, as well as death. Additionally, researchers found that earlier HIV treatment is also cost-effective because it increases survival, prevents costly opportunistic infections and averts transmission of the virus to uninfected individuals.

30 Jul 2012

Paper highlights clinical and immunological activity of immatics’ IMA901 in renal cell carcinoma

immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that key data covering the scientific and clinical development of its lead cancer vaccine, IMA901, have been published in Nature Medicine.

30 Jul 2012

ACT receives Australian patent for human retinal pigment epithelial cells

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that it has been issued a patent in Australia, patent number 2005325753, "Improved modalities for the treatment of degenerative diseases of the retina."

28 Jul 2012

Rituximab also benefits patients with kidney disorder

A drug commonly used to treat immune disorders such as lymphoma and arthritis also benefits patients with an immune disorder of the kidneys that can lead to kidney failure, according to a study appearing in an upcoming issue of new study in the Journal of the American Society of Nephrology (JASN).

28 Jul 2012

Viral evolution and host protein levels predict rapid disease progression in hepatitis C patients

Scientists at the National Institutes of Health have identified several factors in people infected with the hepatitis C virus that may predict whether the unusually rapid progression of disease from initial infection to severe liver conditions, such as cirrhosis, will occur. Knowing whether a patient's condition is likely to deteriorate quickly could help physicians decide on the best course of treatment.

27 Jul 2012

Immune System News and Research

Freiburg scientist receives ERC Starting Grant for NutrImmune project

Teplizumab type I diabetes prevention study now enrolls younger children

IL-10 may improve success rates of skin autografts

Specific autoantibodies associated with blood vessel damage in the brain

Australia's top medical researchers for 2012 announced

TAU researcher reveals link between plant and human biology

Two new targets could enhance the body's defenses against West Nile and hepatitis C

Hydroxychloroquine fails to modify HIV in patients not taking ART

Promising implications for improving cellular immunotherapy for treatment of cancer

UTMB researchers receives NIH grant to develop engineered lung tissue for biomedical studies

Researchers describe new human tissue dendritic cell with cross-presenting function

Scientists decipher molecular causes of life-threatening candida fungal infections

Early ART treatment delays AIDS-related health events in HIV-infected individuals

Paper highlights clinical and immunological activity of immatics’ IMA901 in renal cell carcinoma

ACT receives Australian patent for human retinal pigment epithelial cells

Rituximab also benefits patients with kidney disorder

Viral evolution and host protein levels predict rapid disease progression in hepatitis C patients

Vaccine complex delivered safely by piggybacking onto 3D DNA nanostructures

Lymphoma drug dislodges hidden virus in HIV patients

HIV drug resistance: an interview with Dr. Silvia Bertagnolio

Immunology eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News